The Prevalence of Tardive Dyskinesia in Neuroleptic-Treated Diabetics: A Controlled Study

Linda Ganzini, Ronald T. Heintz, William F. Hoffman, Daniel Casey

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

In a controlled study, we compared the prevalence of tardive dyskinesia in 38 neuroleptic-treated diabetics with the prevalence of tardive dyskinesia in a group of 38 nondiabetic neuroleptic-treated controls, matched for age, sex, psychiatric diagnosis, and dose and duration of neuroleptic treatment. Members of each group were evaluated for movement disorders by a rater who used standard rating scales and was “blind” to all diagnoses and treatments. Neuroleptic-treated diabetics had a significantly higher prevalence and severity of tardive dyskinesia. There were no differences between groups on other possible risk factors for tardive dyskinesia, including parkinsonism, anticholinergic drug treatment, or cognitive function. These data suggest that diabetes mellitus should be examined further as a risk factor for tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)259-263
Number of pages5
JournalArchives of General Psychiatry
Volume48
Issue number3
DOIs
StatePublished - 1991

Fingerprint

Antipsychotic Agents
Movement Disorders
Cholinergic Antagonists
Parkinsonian Disorders
Mental Disorders
Cognition
Diabetes Mellitus
Cross-Sectional Studies
Tardive Dyskinesia
Controlled
Risk Factors
Pharmaceutical Preparations
Cognitive Function
Rating Scales
Drugs
Raters
Dose

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

The Prevalence of Tardive Dyskinesia in Neuroleptic-Treated Diabetics : A Controlled Study. / Ganzini, Linda; Heintz, Ronald T.; Hoffman, William F.; Casey, Daniel.

In: Archives of General Psychiatry, Vol. 48, No. 3, 1991, p. 259-263.

Research output: Contribution to journalArticle

Ganzini, Linda ; Heintz, Ronald T. ; Hoffman, William F. ; Casey, Daniel. / The Prevalence of Tardive Dyskinesia in Neuroleptic-Treated Diabetics : A Controlled Study. In: Archives of General Psychiatry. 1991 ; Vol. 48, No. 3. pp. 259-263.
@article{c81e8159f974439ea5dc0da1db3b036e,
title = "The Prevalence of Tardive Dyskinesia in Neuroleptic-Treated Diabetics: A Controlled Study",
abstract = "In a controlled study, we compared the prevalence of tardive dyskinesia in 38 neuroleptic-treated diabetics with the prevalence of tardive dyskinesia in a group of 38 nondiabetic neuroleptic-treated controls, matched for age, sex, psychiatric diagnosis, and dose and duration of neuroleptic treatment. Members of each group were evaluated for movement disorders by a rater who used standard rating scales and was “blind” to all diagnoses and treatments. Neuroleptic-treated diabetics had a significantly higher prevalence and severity of tardive dyskinesia. There were no differences between groups on other possible risk factors for tardive dyskinesia, including parkinsonism, anticholinergic drug treatment, or cognitive function. These data suggest that diabetes mellitus should be examined further as a risk factor for tardive dyskinesia.",
author = "Linda Ganzini and Heintz, {Ronald T.} and Hoffman, {William F.} and Daniel Casey",
year = "1991",
doi = "10.1001/archpsyc.1991.01810270071010",
language = "English (US)",
volume = "48",
pages = "259--263",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - The Prevalence of Tardive Dyskinesia in Neuroleptic-Treated Diabetics

T2 - A Controlled Study

AU - Ganzini, Linda

AU - Heintz, Ronald T.

AU - Hoffman, William F.

AU - Casey, Daniel

PY - 1991

Y1 - 1991

N2 - In a controlled study, we compared the prevalence of tardive dyskinesia in 38 neuroleptic-treated diabetics with the prevalence of tardive dyskinesia in a group of 38 nondiabetic neuroleptic-treated controls, matched for age, sex, psychiatric diagnosis, and dose and duration of neuroleptic treatment. Members of each group were evaluated for movement disorders by a rater who used standard rating scales and was “blind” to all diagnoses and treatments. Neuroleptic-treated diabetics had a significantly higher prevalence and severity of tardive dyskinesia. There were no differences between groups on other possible risk factors for tardive dyskinesia, including parkinsonism, anticholinergic drug treatment, or cognitive function. These data suggest that diabetes mellitus should be examined further as a risk factor for tardive dyskinesia.

AB - In a controlled study, we compared the prevalence of tardive dyskinesia in 38 neuroleptic-treated diabetics with the prevalence of tardive dyskinesia in a group of 38 nondiabetic neuroleptic-treated controls, matched for age, sex, psychiatric diagnosis, and dose and duration of neuroleptic treatment. Members of each group were evaluated for movement disorders by a rater who used standard rating scales and was “blind” to all diagnoses and treatments. Neuroleptic-treated diabetics had a significantly higher prevalence and severity of tardive dyskinesia. There were no differences between groups on other possible risk factors for tardive dyskinesia, including parkinsonism, anticholinergic drug treatment, or cognitive function. These data suggest that diabetes mellitus should be examined further as a risk factor for tardive dyskinesia.

UR - http://www.scopus.com/inward/record.url?scp=0025980669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025980669&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1991.01810270071010

DO - 10.1001/archpsyc.1991.01810270071010

M3 - Article

C2 - 1671743

AN - SCOPUS:0025980669

VL - 48

SP - 259

EP - 263

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 3

ER -